|
AUPO755097A0
(en)
*
|
1997-06-25 |
1997-07-17 |
University Of Queensland, The |
Receptor agonist and antagonist
|
|
AUPQ339899A0
(en)
|
1999-10-13 |
1999-11-04 |
University Of Queensland, The |
Novel molecules
|
|
ES2353077T3
(es)
|
2000-08-10 |
2011-02-25 |
Mitsubishi Tanabe Pharma Corporation |
Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos.
|
|
JP4751567B2
(ja)
|
2000-09-14 |
2011-08-17 |
田辺三菱製薬株式会社 |
新規アミド誘導体およびその医薬としての用途
|
|
AUPR833401A0
(en)
*
|
2001-10-17 |
2001-11-08 |
University Of Queensland, The |
G protein-coupled receptor antagonists
|
|
ATE525391T1
(de)
|
2002-03-19 |
2011-10-15 |
Cincinnati Childrens S Hospital Medical Ct |
Muteine des c5a anaphylatoxins, für solche muteine kodierende nukleinsäuremoleküle, sowie pharmazeutische verwendungen von muteinen des c5a anaphylatoxins
|
|
WO2003084524A1
(en)
*
|
2002-03-29 |
2003-10-16 |
Neurogen Corporation |
Combination therapy for the treatment of conditions with pathogenic inflammatory components
|
|
AUPS160602A0
(en)
*
|
2002-04-08 |
2002-05-16 |
University Of Queensland, The |
Therapeutic method
|
|
AU2002950657A0
(en)
|
2002-08-08 |
2002-09-12 |
Alchemia Limited |
Derivatives of monosaccharides for drug discovery
|
|
AU2003266858B2
(en)
*
|
2002-10-11 |
2006-09-14 |
Vast Bioscience Pty Limited |
Classes of compounds that interact with GPCRs
|
|
AU2002951995A0
(en)
*
|
2002-10-11 |
2002-10-31 |
Alchemia Limited |
Classes of compounds that interact with gpcrs
|
|
AU2002952086A0
(en)
*
|
2002-10-16 |
2002-11-07 |
The University Of Queensland |
Treatment of osteoarthritis
|
|
ATE509632T1
(de)
*
|
2002-10-16 |
2011-06-15 |
Promics Pty Ltd |
Behandlung von entzündlicher darmerkrankung
|
|
AU2002952129A0
(en)
*
|
2002-10-17 |
2002-10-31 |
The University Of Queensland |
Treatment of hypersensitivity conditions
|
|
AU2003902354A0
(en)
*
|
2003-05-15 |
2003-05-29 |
Harkin, Denis W. |
Treatment of haemorrhagic shock
|
|
AU2003902586A0
(en)
*
|
2003-05-26 |
2003-06-12 |
The University Of Queensland |
Treatment of burns
|
|
WO2005014849A2
(en)
*
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
EP1498422A1
(de)
|
2003-07-17 |
2005-01-19 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
CA2579678A1
(en)
*
|
2004-10-04 |
2006-04-13 |
Alchemia Limited |
Selective inhibitors
|
|
BRPI0606647A2
(pt)
*
|
2005-01-17 |
2009-07-14 |
Jerini Ag |
antagonistas do receptor de c5a
|
|
EP1861114B1
(en)
*
|
2005-03-11 |
2011-02-02 |
Potentia Pharmaceuticals, Inc. |
Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
|
|
EP1739078A1
(de)
|
2005-05-30 |
2007-01-03 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
US20070292421A1
(en)
*
|
2005-07-28 |
2007-12-20 |
Feinberg Bruce B |
Method for treating preeclampsia
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
EP2148691B1
(en)
|
2007-02-05 |
2015-05-20 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
|
|
US20110092446A1
(en)
*
|
2007-07-20 |
2011-04-21 |
Cedric Francois |
Compositions and methods for treatment of trauma
|
|
WO2009121065A2
(en)
*
|
2008-03-28 |
2009-10-01 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
CN102165602A
(zh)
*
|
2008-07-02 |
2011-08-24 |
圣戈班性能塑料谢纳有限公司 |
带框器件、密封件及其制造方法
|
|
JP6223659B2
(ja)
|
2008-11-10 |
2017-11-01 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
補体関連障害を処置するための方法および組成物
|
|
US20130034568A1
(en)
*
|
2010-01-22 |
2013-02-07 |
Georgios Hajishengallis |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
AU2011245117B2
(en)
|
2010-04-30 |
2015-03-12 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies and methods for using the antibodies
|
|
EP2588121A4
(en)
*
|
2010-06-29 |
2013-12-04 |
Univ Nebraska |
C5A ANALOGUE AND USE METHOD THEREFOR
|
|
EP2468295A1
(en)
*
|
2010-12-21 |
2012-06-27 |
Affiris AG |
Vaccines based on peptides of the complement protein C5a
|
|
CA2840270C
(en)
|
2011-06-22 |
2023-09-26 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
WO2014043223A1
(en)
*
|
2012-09-11 |
2014-03-20 |
Hospital For Special Surgery |
Irhom2 inhibition for the treatment of complement mediated disorders
|
|
US10035822B2
(en)
|
2012-11-15 |
2018-07-31 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
US10092620B2
(en)
*
|
2013-04-02 |
2018-10-09 |
The Scripps Research Institute |
Uses of cyclic peptides for treating and preventing atherosclerosis
|
|
AU2014306002B2
(en)
|
2013-08-07 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
|
|
KR20180090785A
(ko)
|
2015-10-07 |
2018-08-13 |
아펠리스 파마슈티컬스 인코포레이티드 |
투여 요법
|
|
MX2019001153A
(es)
|
2016-07-29 |
2019-06-10 |
Pfizer |
Peptidos ciclicos como antagonistas del receptor c5a.
|
|
WO2018081400A1
(en)
|
2016-10-27 |
2018-05-03 |
Alexion Pharmaceuticals Inc. |
Assay for c5b-9 deposition in complement-associated disorders
|
|
DK3411400T3
(da)
|
2017-04-03 |
2021-10-11 |
Inflarx Gmbh |
Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet
|
|
BR112019020955A2
(pt)
|
2017-04-07 |
2020-05-05 |
Apellis Pharmaceuticals, Inc. |
regimes de dosagem e composições e métodos relacionados
|
|
AU2018286754A1
(en)
|
2017-06-23 |
2019-12-19 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5A activity
|
|
JP2021507884A
(ja)
|
2017-12-15 |
2021-02-25 |
アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
投与レジメンならびに関連組成物および方法
|
|
US20220356234A1
(en)
|
2019-10-02 |
2022-11-10 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
|
AU2020438234A1
(en)
|
2020-03-27 |
2022-09-29 |
Inflarx Gmbh |
Inhibitors of C5a for the treatment of corona virus infection
|
|
TW202208427A
(zh)
|
2020-05-06 |
2022-03-01 |
德商因夫萊亞斯有限公司 |
人源化抗ｃ５ａ抗體
|
|
CN115667925A
(zh)
|
2020-05-15 |
2023-01-31 |
阿雷克森制药公司 |
使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途
|
|
WO2024238421A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of biomarkers for the identification and treatment of complement-mediated disorders
|
|
WO2024238422A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
|
|
US12180274B2
(en)
|
2023-05-26 |
2024-12-31 |
Inflarx Gmbh |
Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
|